

Penumbra (PEN) climbs on strong Q4 results and acquisition agreement with Boston Scientific (BSX), deal valued at $14.5B.
You can purchase shares of Penumbra (NYSE:PEN) through any online brokerage.
Other companies in Penumbra’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
Penumbra has a consensus price target of $345.06.
The stock price for Penumbra (NYSE: PEN) is $321.11 last updated November 5, 2026 at 7:00 PM EST.
There are no upcoming dividends for Penumbra.
Penumbra does not have any upcoming earnings scheduled.
There is no upcoming split for Penumbra.
Penumbra is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices...